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This review describes strategies used by a clinical neurologist in the investigation of neurotoxic
disease. It emphasizes the need for a high level of suspicion that environmental substances are
capable of producing impairments in neurologic and neurobehavioral functions. Because of the
difficulties in differentiating neurotoxic from nonneurotoxic disease when presented with
common neurological symptoms, it is necessary to rely upon corroborative evidence from past
medical records, work and environmental histories, and exposure data, as well as detailed
neurological examinations, to reach a conclusion about causation. Sensitive electrophysiologic
and neuropsychologic test batteries are useful in identifying subclinical impairments and in provid-
ing objective confirmation of abnormalities in the central and peripheral nervous systems.
Combining scientific and epidemiologic information with experience and clinical judgment, these
sources of information are used in the formulation of a clinical diagnosis. When many patients
among a group of people are exposed to neurotoxicants, the effects of the exposure may vary
from one to another because of differences in susceptibility, duration of exposure and dosage of
neurotoxicant, and other possible risk factors. Group statistics may obscure a significant effect for
the larger group, despite clinically obvious effects in an individual. The neurologist applies clinical
skills and refers to the accumulated neurotoxicologic literature as a frame of reference to make a
diagnosis about an individual patient or a group of patients who have been exposed to particular
neurotoxicants. The Boston University Environmental Neurology Assessment (BUENA) is a
scheme that attempts to combine epidemiologic methodology and clinical approaches to detect
effects of neurotoxic exposure. The advantages and limitations of such a strategy are discussed.
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Background
The role of the neurologist in identifying different causes of disease of the nervous
neurotoxic hazards is to clarify the patient's system can produce similar symptoms.
complaints that suggest nervous system Essential to the process of differential diag-
dysfunction and to arrive at a correct nosis is a comprehensive past medical his-
anatomical and etiological diagnosis. Many tory and an inquiry into occupational and
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environmental temporal circumstances
surrounding the appearance of symptoms.
With knowledge of the pathophysiologic
mechanisms responsible for the clinical
manifestations and an awareness of the risks
for causing neurotoxic effects characteristic
of certain chemicals, the neurologist brings
a high index of suspicion to the differentia-
tion of neurotoxic syndromes from other
neurologic disorders of nonneurotoxic ori-
gin. In addition, the neurologist can deter-
mine worker fitness and assess risks of
increased susceptibility in a given individ-
ual to known neurotoxicant exposures at
otherwise safe levels (1).
Specific clinical manifestations result
from damage to selected cellular elements
such as the neurons, glial cells, myelin
sheaths, or blood vessels. Central nervous
system structures are affected more by
some chemicals, while the peripheral ner-
vous system is the main target of others.
Certain substances affect both central and
peripheral nervous tissues. Neurologic
impairments result from direct or indirect
effects of a neurotoxicant. Neurotoxic
effects occur when enzymatic protective
mechanisms fail to detoxify the neurotoxi-
cant and eliminate it as a nontoxic by-
product. Neurotoxicants alter function of
the nervous system by changing the lipid
content of cell membranes and damaging
capillary endothelium, by affecting their
ability to transport ions and nutrients, by
interfering with mitochondrial oxidative
processes, and by disturbing neurotrans-
mitter activity. Depending upon the
neurotoxicant, the nature and duration of
exposure, and the vulnerability of the cel-
lular targets, neurotoxic effects may be
reversible or irreversible.
The patient is commonly unaware of
any relationship between any symptoms
and his exposure to particular chemicals.
He simply knows that he feels unwell.
Nonspecific systemic effects of neurotoxi-
cants include vegetative symptoms such as
nausea, dizziness, and headache. The
patient may not recognize changes in his
behavior before they are brought to his
attention by family members or co-work-
ers. Behavioral symptoms such as poor
attention, memory troubles, and delirium
are obvious when they interfere with daily
tasks. Central nervous system symptoms
usually precede the symptoms of peripheral
neuropathy. Early recognition of one case
of neurotoxic disease should raise concern
about possible exposure of other persons
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within the same environment. Continued
exposure may produce effects in the others
in the group, as well as allowing for further
damage to those already affected.
Clinical Approach to Diagnosis
of Neurotoxic Disease
Lists of chemical substances, the industries
in which they might be found, and their
most common neurotoxic effects can be
found in reference books (2,3). Environ-
mental and occupational health informa-
tion can be accessed from various electronic
data systems such as EPA ON-LINE
Library System; National Library of
Medicine (NLM) Hazardous Substances
Data Bank (HSDB) and Toxnet; Integrated
Risk Information System (IRIS), EPA;
Medline and Toxline (Dialog Scientific
Technical Network); National Institute of
Occupational Safety and Health Technical
Information Center (NIOSHTIC), and
CD-ROM (4). With this information, and
by learning from the patient about his work
and environmental background, the clini-
cian can be alerted to the risks of neuro-
toxic exposure. More likely, the patient's
complaints will trigger a search for neuro-
toxic effects (Table 1)(5).
Neurologic Eamination
The neurologist follows a systematic
approach to differentiate nonneurotoxic
disease from neurotoxic disease. A general
medical examination is followed by a
detailed neurologic examination to estab-
lish the clinical-anatomical basis for any
symptom described. Tests of language,
memory, and cognitive performance assess
the patient's mental status. Observations of
gait, posture, muscle tone, fine motor
control, and coordination are made; motor
and sensory functions of peripheral and
cranial nerves are tested. Tendon reflexes
and special reflexes of upper motor neuron
functions are tested. Deviations from
expected performance levels, considered
normal in standard references or as base-
lines in control groups, are recorded as
abnormalities. Similar neurologic signs and
symptoms arise from impairment of partic-
ular neural structures, regardless of the
specific cause of the malady. Selected elec-
trophysiologic and neuropsychologic tests
as well as various blood and urine tests are
needed to confirm the clinical diagnosis
and to separate it from others with similar
presentations. The neurologist should be
able to determine whether there is any
abnormality in the central or peripheral
nervous system and be able to localize a
probable anatomical site of dysfunction.
Evidence of biologic markers and envi-
ronmental exposure data to confirm the
presence of suspected neurotoxicants and
to place the patient in a position to be
exposed must be ascertained. Along with
supporting historical information and bio-
logic and environmental exposure data, the
clinical findings are placed in the context
of the relative importance of each parame-
ter of neurophysiologic and neuropsycho-
logic function to arrive at an overall
diagnosis. These functions, documented by
objective laboratory tests, can be used as
outcomes in formal epidemiologic studies
as well as in the clinical diagnosis of an
individual case of neurotoxic disease.
Electrophysiologic Tests
Eletroencephalography. Bioelectric poten-
tials are generated by the neurons of
the cerebral cortex and transmitted over
complex synaptic networks throughout the
cerebral hemispheres. Changes in these
generated electromagnetic fields are
recorded from the scalp by sensitive elec-
tronic equipment, electroencephalogram
(EEG), and displayed as patterns of mixed
frequencies, amplitudes, and topographical
distributions over the cranium. Under
normal waking conditions, as well as in
natural sleep states, the EEG records pre-
dictable patterns. A mixture of fast and
slow frequencies appear in frontal, tempo-
ral, and occipital areas in a symmetrical
fashion. When the patterns, amplitudes,
and frequencies are affected, an abnormal-
ity of brain function, or encephalopathy, is
suspected. A sudden paroxysmal quality in
the wave forms along with sharp spiky
waves indicates epileptic activity; frontal
slowing of the background with disappear-
ance of the normal resting frequencies is
found in metabolic or toxic brain prob-
lems; a marked difference in symmetry of
the recording suggests a lateralized pathol-
ogy; and a concentration of sharp, slow, or
paroxysmal waves in a focal area reflects a
structural lesion such as a tumor, an
infarct, or an old trauma. The EEG is nor-
mal in patients with dementia of the
Alzheimer type early in its course, but as
in other neurodegenerative diseases,
greater amounts of slowing and disorgani-
zation appear as progression occurs. Acute
EEG changes such as increased amounts of
slow wave activity occur during exposure
to centrally acting neurotoxicants, while
behavioral effects are also observed. The
EEG returns to a normal pattern after
removal from exposure, although behavioral
manifestations may persist clinically or be
detectable on formal neuropsychological
tests. Abnormalities in the EEG are indica-
tors of the physiologic state of the brain only
at the time of recording, and the patterns
are not specific to any particular causal sub-
stance. As with all laboratory tests, clinical
correlation is necessary before significance
can be given to an EEG report (6).
Electromyography and Nern
Conduction Tests
Appropriate use of electrophysiologic tests
not only can localize pathology to individ-
ual nerves, roots, plexus, or motor neurons,
but it also can characterize the pathophysi-
ologic basis for dysfunctions as axonal,
demyelinating, or both (7). A nerve cell
body and its axon connect with other nerve
cells, or neurons, by synapses and to mus-
cle cells by complicated neuromuscular
junctions. Axons of many neurons run
together as fiber bundles constituting a
peripheral nerve made up of thousands of
individual nerve fibers of different sizes.
The diameter of the fiber depends on the
amount of myelin surrounding it-the
more myelin, the larger the fiber diameter.
The amount of myelin surrounding each
nerve axon determines the speed of con-
duction of that axon-the less myelin, the
slower the conduction time, and the more
myelin, the faster the conduction time.
The fastest firing fibers deliver the impulse
first, with the slower fibers conducting later
arriving impulses.
Each electrophysiologic parameter
reflects an aspect of functioning of the
motor and sensory components of a
peripheral nerve. Thus, information about
the integrity of the structures can be
derived from the documented responses to
electrical stimulation.
The complex nerve action potential
recorded from the distal portion of a stim-
ulated nerve includes all the conducted
impulses of the various fiber sizes. The
largest fibers and faster firing fibers deter-
mine the fastest speed of a conducted nerve
impulse, that is, the shortest latency
between the stimulus and the recorded
response. If the number of large fibers is
reduced because of demyelination, such as
by toxic neuropathy, then the latency (mil-
liseconds) between the stimulus and the
recorded response will be prolonged
because it is dependent upon the remain-
ing smaller fibers to carry the impulses. If
axons are damaged, nerve impulses will be
conducted only by those axons remaining
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Table 1. Neurologic symptoms and associated exposures.
Neurologic symptom Neurotoxicant Major uses/sources of exposure
Ataxia Metals
Manganese
Mercury
Solvents
Carbon disulfide
Methyl n-butyl ketone
n-Hexane
Toluene
Monomers
Acrylamide
Insecticides
Organophosphates
Chlorinated hydrocarbons
(DDT, Kepone)
Metals
Arsenic
Lead
Nickel
Tin
Tellurium
Solvents
Carbon disulfide
Methyl n-butyl ketone
n-Hexane
Perchloroethylene
Toluene
Trichloroethylene
Gases
Carbon monoxide
Cognitive impairment
Waste anesthetic gases
Insecticides
Organophosphates
Metals
Arsenic
Lead
Manganese
Mercury
Iron, steel industry; welding operations; metal-finishing operations of high manganese steel;
fertilizers; manufacturers of fireworks, matches; manufacturers using oxidation catalysts;
manufacturers of dry cell batteries
Scientific instruments; electrical equipment; amalgams; electroplating industry; photography;
felt making; taxidermy; textiles; pigments
Manufacturers of viscose rayon; paints; preservatives; textiles; rubber cement; varnishes;
electroplating industry
Paints; lacquers; varnishes; metal-cleaning compounds; quick-drying inks; paint removers
Lacquers; printing inks; stains; pharmaceutical industry; rubber cement; glues
Rubber solvents; cleaning agents; glues; manufacturers of benzene; gasoline, aviation fuels;
paints, thinners; lacquers
Paper, pulp industry; grouting material: basements, tunnels, dams, mine shafts; photography;
dyes; water, waste treatment facilities
Agricultural industry
Pesticides; pigments; antifouling paint; electroplating industry; seafood; smelters;
semiconductors
Solder; lead shot; illicit whiskey; insecticides; auto body shops; storage battery manufacturing
plants; foundries; smelters; lead-based paint; lead-stained glass; lead pipes
Electroplating industry; surgical and dental instruments; nickel-cadmium batteries; paints;
inks; alloys; coinage
Canning industry; silverware; solder; electronic components; polyvinyl plastics;
fungicides; coated wire
Rubber vulcanization; coloring agent in glazes, glass; electronics industry; foundries;
semiconductors; thermoelectric devices
Manufacturers of viscose rayon; preservatives; rubber cement; electroplating industry;
paints; textiles; varnishes
Paints; varnishes; quick drying inks; lacquers; metal cleaning compounds; paint removers
Lacquers; printing inks; pharmaceutical industry; rubber cement; stains; glues
Paint removers; degreasers; extraction agent for vegetable and mineral oils;
dry cleaning industry; textile industry
Rubber solvents; glues; paints; automobile, aviation fuels; paint thinners; cleaning agents;
manufacturers of benzene; lacquers; gasoline
Degreasers; paints; varnishes, lacquers; extraction of caffeine; dry cleaning;
rubber solvents; adhesive
Exhaust fumes of internal combustion engines; acetylene welding; enclosed areas: mines,
tunnels; emissions as a result of incomplete combustion
Operating rooms; dental offices
Agricultural industry
Pesticides; pigments; antifouling paint; electroplating industry; seafood; smelters;
semiconductors
Solder; lead shot; illicit whiskey; insecticides; auto body shops; storage battery manufacturing
plants; foundries; smelters; lead-based paint; lead-stained glass; lead pipes
Iron, steel industry; welding operations; metal finishing; fertilizers; manufacturers of fireworks,
matches, oxidation catalysts, dry cell batteries
Scientific instruments; electrical equipment; amalgams; electroplating industry; photography;
felt making; taxidermy; textiles; pigments
(Continued)
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Table 1. Neurologic symptoms and associated exposures-Continued
Neurologic symptom Neurotoxicant Major uses/sources of exposure
Tremors
Insecticides
Organophosphates
Metals
Arsenic
Lead
Mercury
Thallium
Solvents
Carbon disulfide
Methyl n-butyl ketone
n-Hexane
Perchloroethylene
Trichloroethylene
Monomers
Acrylamide
Metals
Manganese
Mercury
Solvents
Carbon disulfide
Trichloroethylene
Insecticides
Chlorinated hydrocarbons
(DDT, Kepone)
Modified from Feldman and Travers (5).
Manufacturers of viscose rayon; preservatives; rubber cement; electroplating industry;
paints; textiles; varnishes
Paint removers; degreasers; extraction agent for vegetable and mineral oils;
dry cleaning industry; textile industry
Rubber solvents; glues; paints; automobile, aviation fuels; paint thinners; cleaning agents;
manufacturers of benzene; lacquers; gasoline
Degreasers; paints; lacquers, varnishes; dry cleaning industry; rubber solvents; adhesive;
extraction of caffeine
Agricultural industry
Pesticides; pigments; antifouling paint; electroplating industry; seafood; smelters;
semiconductors
Solder; lead shot; illicit whiskey; insecticides; auto body shops; storage battery manufacturing
plants; foundries; smelters; lead-based paint; lead-stained glass; lead pipes
Scientific instruments; electrical equipment; amalgams; electroplating industry; photography;
felt making; taxidermy; textiles; pigments
Rodenticides; fungicides; mercury and silver alloys; manufacturers of special lenses;
photoelectric cells; infrared optical instruments
Manufacturers of viscose rayon; preservatives; rubber cement; electroplating industry;
paints; textiles; varnishes
Paints; varnishes; quick-drying inks; lacquers; metal-cleaning compounds; paint removers
Lacquers; printing inks; pharmaceutical industry; rubber cement; stains; glues
Paint removers; degreasers; extraction agent for vegetable and mineral oils;
dry cleaning industry; textile industry
Degreasers; paints; lacquers, varnishes; dry cleaning industry; rubber solvents; adhesive;
extraction of caffeine
Paper, pulp industry; grouting material: basements, tunnels, dams, mine shafts; photography;
dyes; water, waste treatment facilities
Iron, steel industry; welding operations; metal-finishing operations of high manganese steel;
fertilizers; manufacturers of fireworks, matches, oxidation catalysts, dry cell batteries
Scientific instruments; electrical equipment; amalgams; electroplating industry; photography;
felt making; taxidermy; textiles; pigments
Manufacturers of viscose rayon; preservatives; rubber cement; electroplating industry;
paints; textiles; varnishes
Degreasers; paints; lacquers, varnishes; dry cleaning industry; rubber solvents; adhesive;
extraction of caffeine
Agricultural industry
undamaged, myelinated, or relatively
unmyelinated. The resultant recording will
show a reduction in the amplitude (micro
volts) of the evoked nerve action potential
or an absence of an evoked nerve action
potential. Conduction velocity (meters per
second) is the speed of travel of an evoked
nerve action potential between two sites of
stimulation and a common end point of
recording an electrical or muscle response.
The conduction velocity value is calculated
by subtracting the proximal latency from
the distal latency and dividing the differ-
ence into the distance between the two
sites of stimulation.
Acceptable normal values are usually
those that fall within 1 or 2 standard devia-
tions (SD) from laboratory or control
means. We (8) consider values 2 SD from
the mean abnormal in dinical settings for a
patient; a more limited range of acceptable
values is used from time to time for tests
with greater degrees of variability in
response, such as the direct response of the
blink reflex (9,10). Neurophysiologic test
results that fall anywhere within 2 SD are
therefore considered within the normal
range. However, subtle dysfunction may
exist among many, but not all, of a group
of nerve fibers without affecting the overall
average and fastest conduction time reflect-
ing this partial impairment enough to give
a value outside 2 SD. In such instances,
comparison of the actual mean related
value (MRV) (11) for a given parameter
should be made with the actual MRV of a
Environmental Health Perspectives * Vol 104, Supplement 2 - April 1996
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previous or later test in the same patient.
The MRV would show changes from base-
line, all within the acceptable normal
range of 2 SD for each test, and a signifi-
cant change in the MRV over time would
reveal the relative effects.
In a group of affected individuals,
subclinical toxic neuropathy may be present
although no one member exhibits overt
clinical neurotoxic effect. In this situation,
analysis of the population requires different
statistical approaches such as those for cen-
tral tendencies (means, modes, and medi-
ans). The statistical power of field studies of
toxic neuropathy may uncover a significant
degree of neurotoxic effect below values
usually accepted as clinically normal in
individual patients in an office practice
(12). Subgrouping and unit analysis have
been used to define relationships between
exposure and neurophysiologic impair-
ments as measured by electrophysiologic
techniques (13,14).
Electrophysiologic tests are not applied
uniformly. Differences in techniques and
instrumentation and variables among study
populations often account for inconsis-
tency among the data collected and its
interpretation (15). The clinical neurolo-
gist must take this into account when eval-
uating the results obtained in individual
cases and especially in groups of individu-
als. Published and generally accepted
electrophysiologic procedures should be
used to measure and report motor and sen-
sory latencies and amplitudes of evoked
nerve action potentials and to calculate
conduction velocities (9,16,17).
Neuropsychologic Tests
Acute, mild, transient, and usually
reversible effects of neurotoxicants on the
central nervous system (CNS) are common
experiences of most people who work with
volatile and aromatic substances (e.g., glues
and varnish) or with poor ventilation or
who imbibe ethyl alcohol. Severe acute
effects may include headache, seizures, or
delirium. More chronic manifestations are
less obvious.
Initial stages of neurobehavioral toxicity
include altered affect, depression, sleep dis-
turbances, apathy, fatigue, and diminished
mental efficiency. Persistent mood disor-
ders associated with impaired cognitive
functioning may be symptomatic of toxi-
cant-induced CNS dysfunction but are
sometimes incorrectly attributed to primar-
ily psychiatric causes. It is difficult to
attach a neurotoxic etiology to behavioral
symptoms unless there are corroborative
data indicating exposure. The alleviation of
symptoms upon withdrawal from the
suspected source of exposure to neurotoxi-
cants is a valuable clue to such a relation-
ship. Serial formal neuropsychologic
testing can document changes in perfor-
mance in the various domains of cognitive
and mental function.
The encephalopathy that occurs follow-
ing occupational or environmental expo-
sure to neurotoxicants in adults is usually
characterized by deficits in one or more of
the following functional areas: attention,
executive function, fluency (verbal or
visual), motor abilities, visuospatial skills,
learning and short-term memory, and
mood and adjustment (Table 2) (18).
Neuropsychologic testing determines the
character of a deficit and relates the
findings to other information gathered
from clinical and social evaluations. A
qualified neuropsychologist, experienced in
testing patients with occupational and
environmental neurotoxicant exposures,
will recognize the importance of designing
a test battery that will control for demo-
graphic and cultural variables, premorbid
cognitive status, changes in mood state and
perceptual experiences, energy levels, per-
sonality, and motivational influences. In
addition, the test battery must be able to
recognize the effects of specific neurotoxi-
cants to which the patient is suspected of
having been exposed. These are some ques-
tions to be answered: Do the deficits in test
results explain problems exhibited by the
patient in his daily life? Do the findings
suggest the existence of other disorders
(neurologic, psychiatric, motivational,
developmental, medical)? Are the test
results consistent with those described in
the literature or previously observed in
other cases of neurotoxicant exposure?
What are possible treatment approaches?
The test results are scored and inter-
preted by a qualified neuropsychologist.
Some neurologists have sufficient experience
in behavioral neurology to be able to evalu-
ate the various descriptions of test perfor-
mance and conclusions for each of the
instruments of the test battery. Consid-
eration of other neurologic findings on
examination allows the neurologist as well
as the neuropsychologist to reconcile dis-
crepancies or to corroborate the findings on
anatomical-clinical grounds in the interpre-
tation of test results. The use of imaging
techniques such as computerized axial
tomography or magnetic resonance imaging
are often necessary to exclude brain lesions
such as old traumas, vascular malformations
and other congenital or developmental con-
ditions, neoplasia, or multiple sclerosis-type
demyelinative diseases.
Neurotoxicants produce specific effects
on the hippocampus, while others affect
the white matter, basal ganglia, cerebellum,
frontal lobes, or occipital cortex. Each pos-
sible site of neuropathologic impairment
will be associated with different patterns of
neuropsychologic deficit. The main tasks
in the differential diagnosis of toxic ence-
phalopathies by formal neuropsychologic
testing include characterization of premor-
bid cognitive status; dissociation of the
effects of coexisting psychiatric disorders;
dissociation of the effects of coexisting
medical and neurologic disorders; and dif-
ferentiation of the specific effects of expo-
sure to different neurotoxicants (in cases of
multiple toxicant exposures, substance
abuse, or prescription drug use).
Biologic Markers and Exposure Data
The temporal relationship of symptoms,
circumstances of possible exposure, and
course of disease helps to place the
patient's risk for neurotoxic effects. From
the clinical examination, the neurologist
identifies the impaired functions and infers
the location of probable damage within the
nervous system. The patient may provide
much of the needed information by inter-
view or by completing a questionnaire.
Unless the suspected neurotoxic conditions
still exist when the patient is identified, it is
difficult to obtain timely environmental
exposure measurements. Frequently,
metabolism and excretion of a possible
causal neurotoxicant has occurred before
blood, urine, feces, hair, or nail samples
can be taken, which reduces the chances of
obtaining a tissue level of a neurotoxicant
or its metabolite to verify exposure. Peak
levels of absorbed material may have
passed by the time the possibility of neu-
rotoxic disease is recognized. Prompt
efforts must be made to substantiate expo-
sure while residual levels may still be
detected in the suspected environment as
well as in the patient.
Records of past exposure levels and
safety monitoring data maintained by the
employer or health agencies are useful in
estimating exposures and trying to recon-
struct the circumstances of exposure.
Material Safety Data Sheets from chemical
manufacturers and suppliers direct the clini-
cian to specific compounds and their pecu-
liar characteristics and potential hazards. The
assistance of a qualified industrial and envi-
ronmental hygienist is required in deter-
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Table 2. Neuropsychologic tests used in assessing neurotoxicity.
Domain Description Implications
General intellect
Wechsler IQ tests (WAIS-R,
WISC, WPPSI)
Peabody Picture Vocabulary Test
Stanford-Binet
Wide Range Achievement Test
Attention, executive functioning
Digit span (WAIS-R)
Arithmetic (Wechsler tests)
Trail-making test
Continuous Performance Test
Paced auditory serial addition
Wisconsin Card Sorting Test
Verbal language
Information (Wechsler tests)
Vocabulary (Wechsler tests)
Comprehension (Wechsler tests)
Similarities (Wechsler tests)
Controlled oral word association
Boston Naming Test
Reading comprehension (Boston
Diagnostic Aphasia Exam)
Writing sample
Visuospatial, visuomotor
Picture completion (Wechsler tests)
Digit symbol (Wechsler tests)
Picture arrangement (Wechsler tests)
Block design (Wechsler tests)
Object assembly (Wechsler tests)
Boston Visuospatial Quantitative
Battery
Hooper Visual Organization Test
Rey-Osterreith Complex Figure
Santa Ana Formboard Test
Finger tapping
Memory
Logical memories-immediate and
delayed recall (IR, DR)
(Wechsler Memory Scales)
Verbal impaired associate learning
(DR) (Wechsler Memory Scales)
Figural memory (Wechsler Memory
Scales)
Visual paired associate learning
(IR, DR) (Wechsler Memory Scales)
Visual reproductions (IR, DR)
(Wechsler Memory Scales)
Intelligence measures
Single word comprehension
Intelligence measure
Academic skills in arithmetic, spelling, reading
Digits forward and backward
Oral calculations
Connect-a-dot task requiring sequencing and
alternating sequences
Acknowledgment of occurrence of a critical
stimulus in a series of orally or visually
presented stimuli
Serial calculation test
Requires subject to infer
Information usually learned in school
Verbal vocabulary definitions
Proverb definitions, social judgment,
problem solving
Inference of similarities between
nominative words
Word list generation within
alphabetical or semantic
Naming of objects depicted in line drawings
A direct screening test of simple reading
comprehension
Patient writes to dictation or describes a picture
Identification of missing details in line drawing
Coding task requiring matching symbols to digits
Sequencing of cartoon frames to represent
meaningful stories
Assembly of 3-D blocks to replicate
2-D representations
Assembly of puzzles
Drawings of common objects spontaneously
and to copy
Identification of correct outline of drawings
of cut-up objects
Drawing of a complicated abstract visual design
Knobs in a formboard are turned 180 degrees with
each hand individually and both hands together
Speed of tapping with each index finger
Recall of paragraph information read orally on
immediate and 20-min delayed recall
Two paired words are presented in a list of pairs;
subject must recall second word; test is presented
on immediate and delayed recall
Multiple choice recognition using recognition
(not recall) performance measures
Six visual designs are paired with six colors;
recognition memory is tested immediately
after the six are presented on learning trials
and at delayed recall
Visual designs are drawn immediately after
presentation and at delayed recall
Overall level of cognitive function compared with population norms
Robust measure of verbal intelligence in adults, can be sensitive
to exposure in children
Similar to Wechsler tests
Robust estimate of premorbid ability patterns in adults, can be
sensitive to exposure in children
Measures simple attention and cognitive tracking
Assesses attention, tracking, and calculation
Measures attention, sequencing, visual scanning, speed of processing
Assesses attention
Sensitive measure of attention and tracking speed
Tests ability to think flexibly, decision-making rules
Robust estimate of native abilities in adults
Fairly robust estimate of verbal intelligence, although sensitive to concrete-
ness associated with brain damage (including toxic encephalopathy)
Sensitive to reasoning skill, can be impaired after exposure to
neurotoxicants
Sensitive to reasoning skills, can be impaired after exposure to
neurotoxicants
Assesses flexibility, planning, arousal, processing speed, ability
to generate strategies, somewhat sensitive to exposure
Sensitive to aphasia, also sensitive to native verbal processing deficits
or those acquired through childhood exposure
Sensitive to moderate-to-severe dyslexia, usually insensitive to toxic
exposure in adults
Assesses graphomotor skills, spelling
Measures perceptual analysis
Complex task assessing motor speed, visual scanning, working memory
Measures visual sequencing ability to infer relationships from
visuospatial/social stimuli
Assesses abstract visual construction ability and planning of designs
Measures concrete visual construction skills, Gestalt recognition
Measures constructional abilities, motor functioning
Sensitive to Gestalt integration processing
Sensitive to deficits in visuospatial planning and construction
Measures motor speed and coordination
Sensitive to lateralized manual motor speed
Sensitive to new learning and retention of newly learned information
Measures abstract verbal list IR, learning, retention
Assesses visual recognition and memory
Test of abstract visual learning using recognition (not recall)
performance measures
Measures visual learning and retention
(Continued)
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Table 2. Neuropsychologic tests used in assessing neurotoxicity-Continued.
Domain Description Implications
Delayed Recognition Span Test Based on delayed nonmatching to sample Assesses new learning
paradigm, discs are moved about on a board
to assess recognition memory for words, color,
spatial locations
Peterson Task Words or consonants presented must be Measures sensitivity to interference in new learning
recalled after a period of distraction
California Verbal Learning Test Subject is presented with list of 16 words (which Provides multiple measures of new learning, recall, recognition memory,
can be semantically related) over multiple use of strategies and sensitivity to interference
learning trials and an interference list
Rey-Osterreith (IR, DR) Complex design is drawn from IR Assesses memory for visual information that is difficult to
immediately after it has been copied and at a encode verbally
20-min delayed recall
Personality, mood
Profile of mood states Sixty-five single word descriptors of affective Sensitive to clinical mood disturbance and to affective changes
symptoms are endorsed by degree of secondary to toxicant exposure
severity on six scales
Minnesota Multiphasic Personality True-false responses provided on personality Provides description of current personality function, some scales
Inventory (R) inventory summarized on multiple clinical sensitive to exposure
dimensions
Modified from White et al. (18).
mining sufficient information to validate
the patient's recall of exposure conditions.
In addition, the hygienist can provide
analyses of personal and environmental
samplings for evidence of suspected or
other pollutants.
WVhile it is reasonable to depend upon
the findings and opinions of an expert con-
sultant in area and personal sampling, the
neurologist involved in evaluating the
patient for neurotoxic disease must be
critical when reviewing reports of environ-
mental monitoring and exposure sampling.
Important factors to consider include sen-
sitivity and specificity of sampling and ana-
lytic methods; type of samples (area or
personal sampling); timing of samples; use
of personal protective equipment and
safety practices; consideration of all possi-
ble routes of exposure; and exposure to
combinations of neurotoxicants (19). As in
epidemiologic research, the use of a partic-
ular biologic measurement as a marker of
exposure or effect also requires validation
in the clinical setting. Validity of a marker
is defined in terms of its sensitivity and
specificity. The predictive value of a
marker to accurately identify exposure and
effect is determined not only by the valid-
ity of the test itself, but also by the charac-
teristics of the population to which the test
is being applied.
Clinical relevance of markers should be
interpreted cautiously. Furthermore, there
are a limited number of known neurotoxi-
cants for which exposure can be tested by
biologic sampling in the clinical setting.
For those biologic markers whose clinical
correlations have been well studied, rele-
vant reference values have been established
and should be referred to in confirming the
diagnosis of neurotoxicity in a given
patient or group of patients (20,21).
Formulating a Diagnosis
Findings on general and neurologic exami-
nation that represent a variance from con-
ventionally accepted clinical norms, as
defined in textbooks and reference works
that consider neurologic functions, are
abnormalities. Sets of physiologic,
anatomic, and behavioral concepts and
principles accumulated from experience
and derived from a database of previously
published reports known to the examiner
serve as a frame of reference for evaluating
these abnormalities in formulating a diag-
nosis and in offering a causal explanation.
A clinical diagnosis in a patient is arrived
at by an intellectual process that integrates
all available information in a systematic
manner. This process should be the same
whether used in the day-to-day practice of
clinical medicine or in the special circum-
stances of evaluating self-referred individu-
als suspected of neurotoxic disease and
involved in litigation.
Boston University
Environmental Neurology
Assessment (BUENA)
Diagnosing effects of neurotoxicants rests
on the ability of the clinician to recognize
the risk that certain environmental agents
can cause adverse biologic responses in
nervous tissue at critical levels of exposure
and absorption. A constellation of neuro-
logic effects ranging from subclinical or
barely perceptible sensory deficits to gross
behavioral abnormalities may characterize a
population at risk (22). A high index of sus-
picion is needed to recognize individual
cases or outbreaks of neurotoxic illness in
communities, especially in the absence of a
dramatic accident or an obvious hazardous
waste spill. In communities where potential
hazards, such as chemical waste disposal
sites exist or where manufacturing processes
are located near water supply sources, occur-
rences of exposure can be presumed (23).
Appropriate and sensitive procedures
must be applied for detecting and charac-
terizing disturbances in neurologic and
behavioral functions, as well as document-
ing the nature and extent of any hazardous
conditions. The U.S. Environmental
Protection Agency (U.S. EPA) (24) uses a
multi-tiered laboratory approach for testing
neurotoxicity in animals, in which a variety
of measurements are integrated into a
health or safety index. Such multiple para-
meter screening procedures parallel the
process of human assessment that incorpo-
rates various findings of clinical neurologic
examinations, electrophysiologic measure-
ments of peripheral and CNS functions,
and observations and test scores of stan-
dardized neuropsychologic studies and
leads to a clinical diagnosis.
In an effort to standardize a procedure
for clinical assessment of neurotoxic
disease in individuals as well as in groups,
we have developed the Boston University
Environmental Health Perspectives - Vol 104, Supplement 2 - April 996 233
FELDMAN AND WHITE
Environmental Neurology Assessment
(BUENA) (8). This detailed protocol lists
essential questions to be answered in order
to arrive at a diagnosis of neurotoxic dis-
ease and to eliminate as many confounding
variables as possible.
BUENA
a) Are the data sufficient to identify any or
all complaints as being caused by a
neurotoxin?
. List complaints and relate them on a
time line to all possible exposures to
sources of chemicals (work, home,
hobby)
- Identify symptoms and functional
changes expressed, experienced, and
observed by others; list evidence of
mood, anxiety, sleep disturbances
and effect on quality of life
- Cite time of onset, duration, and
intensity of complaints; indicate
when symptoms worsen or remit
in relation to exposure (e.g., work
week, weekend, time of shift, on
vacation)
- Evaluate subject's family/genetic
health, special sensitivities, and
possible congenital factors
* List all substances and how they are
used (at workplace, in home, hobbies)
- Obtain chemical names (not trade
label names), material safety data
sheets, and other identifying data
concerning each substance
- Review availableworkplace infor-
mation-e.g., Occupational Safety
and Health Administration
(OSHA)-mandated material safety
data sheets and employer training
program materials; employer's
medical records and exposure
records that, if kept by employer,
must be made available under
OSHA rules. Review, if available,
the following: employer's Toxic
Substances Control Act (TOSCA)
8c and 8e reports to U.S. EPA,
employer's community right-to-
know reports to local officials with
regard to hazardous materials
made, used, or sorted on site
* Obtain environmental and industrial
hygiene air measures or drinking-
water samples to prove the presence
of alleged chemicals in the alleged
source. Current levels are important,
but levels taken in relationship to
occurrence of complaints are essential
* Obtain urine and blood samples
from the allegedly affected individu-
als and from known unexposed con-
trol subjects of similar age and occu-
pation, especially at time of
complaints, to establish body burden
of chemical
* For suspect chemicals, develop infor-
mation on dose-response relation-
ships, animal studies, toxicologic and
epidemiologic studies
b) Are the complaints substantiated by
clinical neurologic physical examination,
standardized neuropsychologic and neu-
rophysiologic tests, and appropriate
blood and urine analyses? Also, are the
complaints corroborated by epidemio-
logic, toxicologic, or animal studies;
by National Institute for Occupational
Safety and Health (NIOSH), OSHA,
or U.S. EPA studies of the workforce or
community; by employer studies and
reports to U.S. EPA or OSHA (e.g.,
TOSCA 8c and 8e reports)?
c) Are the findings due to a primary
neurologic disease or other medical
conditions?
d) Are the findings on examination
explained by any other causal factors in
past medical history, previous or cur-
rent unrelated exposures to substances
from sources other than the one under
consideration?
* Time line of past jobs, residences
* Time line of past medical history
e) Analyze individual cases for confirma-
tory studies and group data for cluster
analysis or population statistical study
f ) Identify and critically review previously
published or reported cases, case-con-
trol studies, population studies, and
animal studies concerning the alleged
neurotoxins and relate documentation
to case data
g) Estimate the damage consequences for
the subject: disease, anxiety, loss of con-
sort, functional impairments; need for
special education, counseling, medical
surveillance, or medical therapeutic
measures; job disability, loss of earn-
ings, etc.
h) Reevaluate after reasonable absence
from all neurotoxic exposure to assess
course of progression, recovery, or
persistent impairment or disability.
This approach formalizes techniques as
they are used in the everyday practice of
medicine, where the goal is to assess impair-
ments of an individual within his environ-
ment. In this context, differing from the
traditional epidemiologic study, the clini-
cian takes the position that even a small
probability of serious illness must not be
dismissed (25).
While the data collected by BUENA do
not meet conventional criteria of an
epidemiologic design, they are nevertheless
reliable from scientific, clinical, and legal
points of view. Rothman et al. (26), in
arguing against the use of significance
testing as the sole criterion on which to
judge scientific validity in epidemiology,
strongly supported the notion that reanaly-
sis and metaanalysis of observed associa-
tions between suspected risk factors and
medical conditions provides valid and use-
ful evidence. If it were practical to design a
more conventional epidemiologic study,
then all the parameters, including concur-
rent control subjects and exposure data
measures for much larger groups of sub-
jects, would be needed for proper statistical
analysis. Thus, without an elaborate epi-
demiologic design to which traditional sta-
tistical analyses can be applied, the results
of studying small groups or well-studied
exposed people can be valuable in support-
ing the concept that environmental factors
play a role in causing neurologic disorders.
By using a consistent protocol and conven-
tional test instruments, the neurophysio-
logic and neuropsychologic performance of
many patients, and groups of patients
exposed to the same neurotoxicants, can be
compared for possible generalizations.
The BUENA was used in studies of
people in three separate communities
suspected of having been exposed to drink-
ing water containing trichloroethylene and
other volatile organic compounds (8).
These findings are summarized and dis-
cussed to demonstrate an effort to compare
the study groups.
Group I included 28 members (9-55
years of age) of 8 families from Woburn,
Massachusetts, who used well water from
< 1 to 12 years. Water from the wells
(9,11) was found to contain trichloroethyl-
ene (63-400 ppb), tetrachloroethylene (21
ppb), chloroform (12 ppb), dichloroacety-
lene (28 ppb), and trichlorotrifluoroethane
(23 ppb). Principal complaints (years after
the end of exposure) included mood
changes (89%), depression (82%), fatigue
(79%), impaired concentration (75%),
headache (71%), and impaired memory
(61%). Reflex changes (92%) and sensory
impairments (14%) with clinical evidence
of peripheral neuropathy (75%) were the
main features on neurologic examination.
Individual test parameters of neurophysio-
logic functions revealed reduced proximal
motor nerve action potential amplitudes
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and distal sensory amplitudes, distal sen-
sory and motor latencies, and prolonged
direct responses (RI) of the trigeminal-
facial nerves blink reflex circuit. As a
group, the RI blink reflex differed signi-
ficantly (p < 0.000 1) from a comparison
group. Subclinical neuropathy presented as
was indicated by abnormalities in the neu-
rophysiologic test responses in several
patients; in those with abnormal clinical
reflexes, a diagnosis of peripheral neuropa-
thy was made in 21 (75%) members of the
group. Neuropsychologic testing showed
that memory was the most affected behav-
ioral domain (89%). Significant impair-
ments were also seen in attention/executive
functions (68%), manual motor function
(61 %), and visuospatial skills (61 %).
Language/verbal functions were within
expected limits. Overall, 24 (86%) of the
people in this group were diagnosed as
having mild to moderate encephalopathy.
Group II included 12 residents (12-68
years old) of a community located near
Alpha, Ohio. Their homes were situated
within 2,000 ft of a manufacturing com-
pany that used solvents in degreasing
operations from 1951 through 1972.
These included trichloroethylene, trichlor-
oethane, tetrachloroethylene, sodium
hydroxide, potassium permanganate, and
phosphoric acid. Trichloroethane was sub-
stituted for trichloroethylene in 1972. It
was established that an average of 50,000
gal per day of waste water flowed into a
surface drainage ditch from 1951 through
1981. In 1986, well water serving these
homes was found to be contaminated.
Thirteen of 31 wells sampled were found to
contain 1,1,1-trichloroethane (up to 2,569
ppb) and trichloroethylene (up to 760
ppb). Well water supplied to two of these
residences also contained tetrachloroethyl-
ene (16.5 ppb), cis-1,2-dichloroethane
(23.9 ppb), and 1,1-dichloroethane (21.7
ppb). 2-Butanone (120 ppb) was detected
in one sample of water. It was suspected
that the residents had been exposed to
volatile organic compounds for 5 to 17
years. Two years after exposure to this
water source had ended, the blood levels in
these 12 individuals from these homes
showed normal or mildly elevated levels of
trichloroethylene and elevated levels of
1,1,1-trichloroethane, ethylbenzene, and
xylene. Neurologic examination revealed no
obvious abnormalities. Evidence of periph-
eral neuropathy included electrophysiologic
abnormalities in nerve conduction parame-
ters greater than 2 SD from the comparison
group mean. Blink reflex measurements
were normal. Neuropsychologic assessment
showed that the most commonly affected
behavioral domain was attention/executive
function (83%). Memory was abnormal in
58% of the subjects.
Group III consisted of 14 people in
Minnesota (8-62 years old) who were
suspected of being exposed for 0.25 to 25
years to well water contaminated with
volatile organic compounds. Six subjects
were exposed to one well containing the
following: trichloroethylene (peak level of
350 ppb), 1,1-dichloroethylene (peak level,
12 ppb), 1,2-dichloroethylene (peak level,
140 ppb), and 1,2-trans-dichloroethylene
(peak level, 85 ppb). Eight others were
served by wells with trichloroethylene
levels ranging from 1,220 to 2,440 ppb.
The BUENA was performed on group III
members 4 to 22 years after the end of
exposure to the contaminated well water.
Neurologic examination showed reflex
abnormalities in 79% and signs of peri-
pheral neuropathy in 35%. Electrophys-
iologic tests of 20 parameters of peripheral
nerve conduction function were measured
in all 14 test subjects. Not all had the com-
plete battery, but the most common abnor-
malities included prolonged ulnar sensory
latency (71%), prolonged median sensory
latency (45%), sural sensory latency (25%),
and ulnar sensory amplitude (33%).
Neuropsychologic tests were done on six
members of one family, two parents and
four young adult children. All six showed
signs of impairment on memory testing
and on tests of attention/executive func-
tion. All four children displayed below
average performance on academic tests and
on language/verbal tasks.
Metaanalysis of the Results ofthe
Three Study Groups
The clinical, electrophysiologic, neuropsy-
chologic, and exposure data, and other rele-
vant demographic information obtained by
the BUENA on each member of the three
groups were reviewed (Table 3)(8). Clinical
features or neurophysiologic studies appear
to be less sensitive than neuropsychologic
assessment as an indicator of group effects.
Neurophysiologic measurements, however,
were very useful in identifying evidence of
subclinical or confirming clinical peripheral
neuropathy in individual subjects. In all
three groups, rates of diagnosis of abnormal
neuropsychologic test results were higher
than the expected rates of abnormal find-
ings for the general population in the
United States. The neuropsychologic para-
meters most frequently affected were in the
domains of memory and attention/execu-
tive function. In general, patients did not
show patterns of impaired test performance
expectable on the basis of dysphoria alone,
e.g., inconsistent responses, generalized
slowing, and failures.
Explanations for differences among and
between the three groups may be found in
the availability and timeliness of the expo-
sure data, the methods of analysis of the
neurophysiologic test results, and in certain
differences in the administration of aspects
of the neuropsychologic test batteries.
Exposure levels were simply those measured
in the well water and not consistently deter-
mined as biologic exposure markers in the
exposed people. Furthermore, the water
concentrations were determined before,
sometimes years before, the clinical testing
was done. Cumulative exposures (cumexp)
were obtained by multiplying the average
exposure (ppb) by the duration of exposure
(years). For purposes of analysis of current
clinical and paraclinical findings, the
cumexp was multiplied by the reciprocal of
the interval (years) between the time when
exposure stopped and the time of clinical
assessment (cumexpad). A chi-square test of
correlation coefficient showed no statisti-
cally significant differences among the
groups in terms of the relationship between
cumexp or cumexpad and symptoms, signs,
or abnormal neurophysiologic parameters.
Average abnormalities in the neurophys-
iologic studies did not appear to be related
to the cumulative exposure on a group
basis. However, on an individual basis,
Table 3. Demographic information and exposure data in three communities with trichloroethylene exposure in
water.
Group I, Group II, Group Ill,
Massachusetts Ohio Minnesota
Number examined 28 12 14
Age range 9-55 years 12-68 years 8-62 years
Exposure levels 63-400 ppb 3.3-330 ppb 261-2,440 ppb
Duration of exposure <1-12 years 5-17 years 0.25-25 years
Time between exposure and exam Approximately 5 years 1-5 years 4-22 years
Data from Feldman et al. (8).
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there was a significant correlation (Pearson)
between symptoms, signs, and abnormal
electrophysiologic measures in whatever
pairs. The linear regression equation also
indicated a slope significantly different
from zero when symptoms, signs, and
abnormal electrophysiologic parameters
were compared. In analyzing the neuro-
physiologic data, a simple application of
the mean and standard deviation was con-
sidered insufficient since nerve conduction
study data are thought not to follow a
normal distribution (27).
We standardized the data on the values
of the electrophysiologic test results of
neurophysiologic functions in normal con-
trols by comparing them to the Gaussian
distribution, using graphical fitness, kur-
tosis, skewness, and equation, and trans-
forming the values where the fitness was
considered unsuitable. Transformation
modes employed included natural log, log
10, cube root, square root, inverse, and
negative inverse. Results were reviewed
and the best transformation was chosen
based on goodness of fit, skewness, kurto-
sis, and the need to work with the non-
transformed values, if reasonable. The
values for each case were converted to the
working values, and the z scores, or mean
related values, were calculated (11). Values
above 2 were regarded as abnormal. The
results on each patient was assessed for the
absolute numbers and the proportion of
abnormal electrophysiologic responses.
Differences in performance on neu-
ropsychologic tests assessing motor speed
among the three groups reflect the varia-
tions in application of some of the instru-
ments of the battery. In group II, the Santa
Ana Form Board was not given. In this
group motor speed apparently was less
affected than in the other two groups.
Visuospatial function was affected in over
half of group I members, but much less
affected according to the test results in the
other two groups, possibly because they
were not given the Sticks test, a particularly
complex task that may have been more
sensitive than the other tests used. As stated
above, memory test performance was often
impaired in these patients. On the older
Wechsler Memory Scale (WMS) given to
group I, performances on visual reproduc-
tion and logical memory tasks were below
expectation. However, these tasks differed
from those used in the revised form of the
WMS (WMS-R) that was administered to
groups II and III, in which figural memory
was the task that proved to be the most
difficult. Performance on digit span and the
Wisconsin Card Sorting Test was also
impaired. The word triad task was difficult
for most subjects in all three groups, as were
digit span and Santa Ana.
Conclusion
The clinical neurologist is helpful in the
identification of the hazards of neurotoxi-
cants in order to distinguish symptoms
that are caused by chemicals from symp-
toms that arise from nonneurotoxic dis-
eases. Often, clinical manifestations of
neurotoxicants are similar to those due to
idiopathic neurologic disease, and exposure
data and historical corroboration the only
indications of probable environmental or
occupation risk.
A systematic approach to the neuro-
logic examination and the application of
consistent and conventional neurophysio-
logic and neuropsychologic confirmatory
tests are needed for identifying chemical
effects. BUENA is a critical approach to
putting the clinical neurologic findings in
the context of exposure and possible
causal relationships.
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